Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? MacPhail A, Attwood LO, Rogers BA. J Antimicrob Chemother 2026;81:dkaf471.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

MacPhail A, Attwood LO, Rogers BA. Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? J Antimicrob Chemother 2026;81:dkaf471.
PMID: 41549653